Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer

SIMPLE SUMMARY: With an overall 5-year survival of only 20% for advanced-stage ovarian cancer patients, enduring and effective therapies are a highly unmet clinical need. Current standard-of-care therapies are able to improve progression-free survival; however, patients still relapse. Moreover, immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Caro, Aarushi Audhut, Deschoemaeker, Sofie, Allonsius, Lize, Coosemans, An, Laoui, Damya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406463/
https://www.ncbi.nlm.nih.gov/pubmed/36011029
http://dx.doi.org/10.3390/cancers14164037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406463/
https://www.ncbi.nlm.nih.gov/pubmed/36011029
http://dx.doi.org/10.3390/cancers14164037

Ejemplares similares